Starting with Exelixis’ condition on in-house dispensing data, manufacturers are introducing a new approach to 340B claims focused on transparency.
|Articles|May 11, 2011
Johnson & Johnson finds traces of fungicide in HIV drug Prezista
BANGALORE (Reuters) - Johnson & Johnson unit Janssen said it was in discussions with regulatory authorities in Europe and Canada to address trace amounts of a fungicide found in certain lots of its HIV drug Prezista (darunavir).
Advertisement
Advertisement
Related to this article
With obesity, muscle loss, and sleep disorders so prominent in postmenopause, providers are now looking into further expansion of GLP-1 use.
Menopause status and symptoms are inconsistently captured in electronic health records, leaving a gap in care for patients.
As midterm elections approach, the pharmacy industry is backing one of its most meaningful bills yet while the current congressional session wanes.
Data found reduced cardiovascular risk with hormone therapy, particularly among Black women and those starting treatment within 10 years of menopause.
Eli Lilly’s new indication helps improve medication delivery for adults with type 2 diabetes, reducing annual injections by over 300.
Pennsylvania has become the center of the outbreak as cases exceed 775 alongside conflicting mortality reports.
The LATA trial found long-acting cabotegravir–rilpivirine is better than daily oral therapy at keeping adolescents virologically suppressed.
Advertisement
Advertisement
Trending on Drug Topics
1
Injectable HIV Treatment Beats Daily Pills in Adolescent Trial
2
FDA Approves Onswik Weekly Insulin for Adults With T2D
3
Study Finds Reduced Cardiovascular Risk With Hormone Therapy Initiation
4
Muscle Preservation Is Key in GLP-1 Therapy for Postmenopausal Women
5